News

The completed HPAPI capacity expansion covers the addition of two new cGMP kilo-lab suites fully dedicated to the development of small and mid-scale cGMP manufacturing of custom HPAPIs (at high containment levels of OEB5 & OEB6) ...

The Asian market is a composite field made of multiple level demands in terms of pricing, volumes, quality. Many pharmaceuticals companies...

I believe the current dynamics of CDMO/Client interaction will remain very similar to where we are now regardless of market conditions. However, as the CDMO industry is extremely competitive....

Sustainability has been a frequently mentioned concept over the last few years across many manufacturing platforms but more recently has become a popular topic within the pharmaceutical industry.

As generic competition increases it is crucial to examine different ways to improve efficiency and cost reduction in the manufacturing process for the active pharmaceutical ingredient (API).

The active pharmaceutical ingredient (API) is the foundation of a final drug product and is a crucial consideration when choosing a Contract Development and Manufacturing Organisation (CDMO) or Contract Research (in House) Development and Manufacturing Organisation (CRDMO).

Drugs & APIs shortage is a global issue with an evident impact affecting all the people independently of their geographic or economic position.

Over the past 10+ years the pharmaceutical Industry has utilized CDMO’s at an increasing level from year to year never seen prior to this period...

Today CDMOs face excellent growth opportunities in a pharmaceutical market environment where using  outsourcing services is becoming the new norm...

Facing the rising number of custom HPAPIs demand, Angelini Fine Chemicals decided to expand its HPAPI capacity at its Aprilia,Italy plant site